Does Mebendazole Interact with Ribociclib?
There is no documented drug-drug interaction between mebendazole and ribociclib based on available evidence, and concurrent use appears safe from a pharmacokinetic perspective.
Pharmacokinetic Rationale
The FDA drug label for ribociclib provides comprehensive drug interaction data that does not identify mebendazole as an interacting medication 1. The key metabolic pathways are:
Ribociclib Metabolism
- Primary elimination: Hepatic metabolism (~84% of total elimination), predominantly via CYP3A4 1
- Minor pathways: CYP enzymes that ribociclib inhibits include CYP1A2, CYP2E1, and CYP3A4/5 at clinically relevant concentrations 1
- No inhibition of: CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 1
Mebendazole Metabolism
Mebendazole is metabolized primarily by hepatic CYP enzymes, but not predominantly by CYP3A4. It undergoes metabolism mainly through other pathways that do not overlap significantly with ribociclib's inhibitory profile.
Clinical Considerations
What Matters for This Patient
For a postmenopausal woman receiving ribociclib 400 mg daily for HR-positive breast cancer:
- No dose adjustment needed for either medication when used concurrently
- Monitor for: Standard ribociclib toxicities (neutropenia, QTc prolongation, hepatotoxicity) regardless of mebendazole use 2
- Mebendazole duration: Typically short-term (3-5 days for most parasitic infections), minimizing any theoretical interaction risk
Drugs That DO Interact with Ribociclib
The FDA label clearly identifies problematic combinations 1:
Avoid or use with extreme caution:
- Strong CYP3A4 inhibitors (e.g., ritonavir): Increase ribociclib exposure 3.2-fold
- Strong CYP3A4 inducers (e.g., rifampicin): Decrease ribociclib exposure by 89%
- CYP3A4 substrates (e.g., midazolam): Ribociclib increases their exposure 3.8-fold
- Tamoxifen: Ribociclib increases tamoxifen exposure 2-fold; not recommended for concurrent use 1
Common Pitfall
The most important consideration is ensuring this patient is not receiving tamoxifen concurrently with ribociclib, as the combination increases tamoxifen exposure approximately 2-fold and is specifically contraindicated 1. The clinical scenario describes appropriate therapy (ribociclib with endocrine therapy), but verify the specific endocrine agent is an aromatase inhibitor or fulvestrant, not tamoxifen.
Monitoring Recommendations
Continue standard ribociclib monitoring 2:
- Neutropenia surveillance: CBC every 14 days for first two cycles, then at start of each cycle
- QTc monitoring: Baseline and periodic ECGs
- Hepatic function: Regular liver function tests (ribociclib can cause hepatotoxicity in 8.3% of patients) 2
Mebendazole does not alter these monitoring requirements.